AML (Acute Myeloid Leukemia)
Oncology·MeSH: Leukemia, Myeloid, Acute
Prevalence
30.0 / 100K
1 drug in development·1 company·1 clinical trial
Drug Pipeline by Phase
Phase 4(1)
| Drug | Company |
|---|---|
| cyp1a2 | RIGEL PHARMACEUTICALS INC (RIGL) |
Frequently asked questions
How many drugs are in development for AML (Acute Myeloid Leukemia)?
BioSniper tracks 1 drug in development for AML (Acute Myeloid Leukemia) across 1 company.
How many clinical trials target AML (Acute Myeloid Leukemia)?
There are 1 clinical trial targeting AML (Acute Myeloid Leukemia) tracked by BioSniper.
What is the prevalence of AML (Acute Myeloid Leukemia)?
The estimated prevalence of AML (Acute Myeloid Leukemia) is approximately 30.0 per 100,000 population.
Deep-dive into AML (Acute Myeloid Leukemia)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis